These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31400985)

  • 1. Preliminary results of the evaluation of the California Hub and Spoke Program.
    Darfler K; Sandoval J; Pearce Antonini V; Urada D
    J Subst Abuse Treat; 2020 Jan; 108():26-32. PubMed ID: 31400985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of the hub and spoke model for opioid use disorders in California: Rationale, design and anticipated impact.
    Miele GM; Caton L; Freese TE; McGovern M; Darfler K; Antonini VP; Perez M; Rawson R
    J Subst Abuse Treat; 2020 Jan; 108():20-25. PubMed ID: 31399272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.
    Reif S; Brolin MF; Stewart MT; Fuchs TJ; Speaker E; Mazel SB
    J Subst Abuse Treat; 2020 Jan; 108():33-39. PubMed ID: 31358328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.
    Rawson RA; Rieckmann T; Cousins S; McCann M; Pearce R
    Prev Med; 2019 Nov; 128():105785. PubMed ID: 31362002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. System-level factors shaping the implementation of "hub and spoke" systems to expand MOUD in rural areas.
    Snell-Rood C; Willging C; Showalter D; Peters H; Pollini RA
    Subst Abus; 2021; 42(4):716-725. PubMed ID: 33284083
    [No Abstract]   [Full Text] [Related]  

  • 6. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
    Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
    J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program.
    Nyaku AN; Zerbo EA; Chen C; Milano N; Johnston B; Chadwick R; Marcello S; Baston K; Haroz R; Crystal S
    BMC Health Serv Res; 2024 Feb; 24(1):179. PubMed ID: 38331802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to primary care physicians prescribing buprenorphine.
    Hutchinson E; Catlin M; Andrilla CH; Baldwin LM; Rosenblatt RA
    Ann Fam Med; 2014; 12(2):128-33. PubMed ID: 24615308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth and Distribution of Buprenorphine-Waivered Providers in the United States, 2007-2017.
    McBain RK; Dick A; Sorbero M; Stein BD
    Ann Intern Med; 2020 Apr; 172(7):504-506. PubMed ID: 31905379
    [No Abstract]   [Full Text] [Related]  

  • 10. Multi-model implementation of evidence-based care in the treatment of opioid use disorder in Pennsylvania.
    Kawasaki S; Francis E; Mills S; Buchberger G; Hogentogler R; Kraschnewski J
    J Subst Abuse Treat; 2019 Nov; 106():58-64. PubMed ID: 31540612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine prescribing practice trends and attitudes among New York providers.
    Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
    J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. West Virginia's model of buprenorphine expansion: Preliminary results.
    Winstanley EL; Lander LR; Berry JH; Mahoney JJ; Zheng W; Herschler J; Marshalek P; Sayres S; Mason J; Haut MW
    J Subst Abuse Treat; 2020 Jan; 108():40-47. PubMed ID: 31221524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescribing patterns of buprenorphine waivered physicians.
    Thomas CP; Doyle E; Kreiner PW; Jones CM; Dubenitz J; Horan A; Stein BD
    Drug Alcohol Depend; 2017 Dec; 181():213-218. PubMed ID: 29096292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empowering Psychiatric Mental Health Nurse Practitioners to Expand Treatment Opportunities for Veterans With Opioid Use Disorder.
    Jones J; Tierney M; Jacobs G; Chien SY; Mallisham S
    J Addict Nurs; 2020; 31(4):261-268. PubMed ID: 33264198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From policy to practice: Pilot program increases access to medication for opioid use disorder in rural Colorado.
    Sorrell TR; Weber M; Alvarez A; Beste N; Hollins U; Amura CR; Cook PF
    J Subst Abuse Treat; 2020 Jul; 114():108027. PubMed ID: 32527514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives.
    Bergman AA; Oberman RS; Taylor SL; Kranke B; Chang ET
    J Gen Intern Med; 2024 Jul; 39(9):1690-1697. PubMed ID: 38587730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine.
    Brunet N; Moore DT; Lendvai Wischik D; Mattocks KM; Rosen MI
    Subst Abus; 2022; 43(1):39-46. PubMed ID: 32078492
    [No Abstract]   [Full Text] [Related]  

  • 19. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians.
    Andrilla CHA; Moore TE; Patterson DG
    J Rural Health; 2019 Jan; 35(1):113-121. PubMed ID: 30339720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.